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INTRODUCTION
Hematopoietic stem cells (HSCs) are an important target for gene 
therapy. A major task in HSC gene therapy is the site-specific modi-
fication of the HSC genome using artificial site-specific endonucle-
ases (EN) that target a DNA break to preselected genomic sites. ENs 
are employed to knockout genes, correct frame shift mutations, 
or to knock in a wild-type cDNA into the endogenous site or het-
erologous sites. There are now a number of different EN platforms 
to generate site-specific DNA breaks in the genome.1 One group of 
ENs contains DNA-binding protein domains. This group includes 
meganucleases with DNA binding and nuclease properties as well 
as zinc-finger nucleases (ZFNs) and transcription activator-like 
effector nucleases (TALENs) in which the DNA-binding domain is 
fused with the bacterial endonuclease FokI. Because DNA cleav-
age by FokI requires two FokI molecules bound to each of the 
DNA strands, two subunits of the FokI containing ENs have to be 
expressed. A  second group of ENs is based on RNA-guided DNA 
recognition and utilizes the CRISPR/Cas9 bacterial system. Several 
approaches have been used to deliver EN expression cassettes to 
HSCs. Because it is thought that the ENs need to be expressed only 
for a short time to achieve permanent modification of the target 
genomic sequence, most of the EN cassette delivery systems allow 
only for transient expression of ENs without integration of the EN 
gene into the host genome. Among these delivery systems are: (i) 
Electorporation of plasmid, minicircle, or mRNA encoding ENs. While 
avoiding the problems associated with viral gene delivery vectors, 
electroporation of plasmid DNA can be associated with cytotoxic-
ity in primary cells especially in HSCs.2,3 This method may not be 
applicable for in  vivo HSC transduction, which can be a prerequi-
site for the application of some EN-based gene-editing approaches. 
(ii) Infection with integrase-defective, nonintegrating lentivirus 
vectors.2 Limitations of this approach can include relatively low 
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Genome editing with site-specific endonucleases has implications for basic biomedical research as well as for gene therapy. 
We generated helper-dependent, capsid-modified adenovirus (HD-Ad5/35) vectors for zinc-finger nuclease (ZFN)– or transcrip-
tion activator-like effector nuclease (TALEN)–mediated genome editing in human CD34+ hematopoietic stem cells (HSCs) from 
mobilized adult donors. The production of these vectors required that ZFN and TALEN expression in HD-Ad5/35 producer 293-Cre 
cells was suppressed. To do this, we developed a microRNA (miRNA)-based system for regulation of gene expression based on 
miRNA expression profiling of 293-Cre and CD34+ cells. Using miR-183-5p and miR-218-5p based regulation of transgene gene 
 expression, we first produced an HD-Ad5/35 vector expressing a ZFN specific to the HIV coreceptor gene ccr5. We demonstrated 
that HD-Ad5/35.ZFNmiR vector conferred ccr5 knock out in primitive HSC (i.e., long-term culture initiating cells and NOD/SCID 
repopulating cells). The ccr5 gene disruption frequency achieved in engrafted HSCs found in the bone marrow of transplanted 
mice is  clinically relevant for HIV therapy considering that these cells can give rise to multiple lineages, including all the lineages 
that represent targets and reservoirs for HIV. We produced a second HD-Ad5/35 vector expressing a TALEN targeting the DNase 
hypersensitivity region 2 (HS2) within the globin locus control region. This vector has potential for targeted gene correction in 
hemoglobinopathies. The miRNA regulated HD-Ad5/35 vector platform for expression of site-specific endonucleases has numerous 
advantages over currently used vectors as a tool for genome engineering of HSCs for therapeutic purposes.
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EN expression levels and epigenetic silencing of the EN cassette,4,5 
limited insert capacity (<8 kb) of lentivirus vectors, and the poten-
tial risk of recombination between identical sequences when two 
EN-FokI units are expressed from the same vector. (iii) Transduction 
with capsid-modified Ad5/35 adenovirus vectors.6 Ad5/35 vectors 
contain fibers derived from human serotype Ad35. Ad5/35 vectors 
target CD46, a receptor that is ubiquitously expressed on 100% of 
CD34+ cells.7 Ad5/35 vectors efficiently transduce HSCs, includ-
ing quiescent primitive HSCs.6–10 The Ad5/35 vectors platform was 
recently used in clinical studies to express a ZFN in T cells.11,12 Ad5/35 
vectors used in these studies were first-generation (E1/E3-deleted) 
vectors. Despite the absence of trans-activating E1 gene products, 
first-generation vectors express low levels of early (E2A and E4) and 
late (pIX, fiber, hexon) genes in transduced cells, which may be asso-
ciated with cytotoxicity in HSCs, especially at elevated doses.13,14 
Toxicity related to leaky viral gene expression can be circumvented 
by the use of helper-dependent (HD) Ad5/35 vectors that lack all 
viral genes.15–18 Growth of HD-Ad vectors depends on coinfection of 
the producer cells with helper Ad vector, which provides all neces-
sary Ad proteins in trans. Removal of helper virus from HD vector 
preparations is based on Cre-recombinase-mediated excision of the 
packaging signal flanked by loxP sites during coinfection.19 HD-Ad 
amplification is done in 293 cells expressing Cre recombinase (293-
Cre). cGMP manufacturing of HD-Ad vectors is established (clinical 
trial locator: NCT01433133, NCT00542568).
We have previously shown that HD-Ad5/35 vectors efficiently 
transduce human CD34+ cells in vitro without significant signs of 
cytotoxicity.17,18,20 The HD-Ad5/35 vector platform has major advan-
tages for HSC genome engineering. HD-Ad5/35 vectors transduce 
primitive subsets of HSCs, have a large capacity (~30 kb) that can 
accommodate large payloads, including several EN expression 
cassettes and homologous donor template,18 and can be used for 
transducing in vivo HSC after intravenous injection.21 HD-Ad5/35 
vectors do not integrate into the genome implying that transgene 
expression is transient. In the past, it has been challenging to gen-
erate HD-Ad5/35 vectors expressing ZFNs or TALENs. During Ad 
amplification in 293 cells, massive amounts of transgene are pro-
duced. This is a problem if overexpression of transgene from the 
vector is potentially cytotoxic. High levels of EN expression is poorly 
tolerated in Ad producer 293 cells, which prevents the rescue of 
vectors or selects for recombined vector genomes and deletion of 
EN expression cassettes. Notably, Ad replicates through a single-
stranded DNA intermediate which enables efficient intramolecular 
recombination between repeated sequences in the viral genome. 
Early production of EN-expressing first-generation Ad vectors often 
involved either the separation of the two EN subunits into two sepa-
rate vectors which are then coinfected to reconstitute EN activity22 
or the suppression of EN expression in 293 cells using inducible 
systems.11,23 Among our attempts to produce CCR5 ZFN-expressing 
HD-Ad vectors was a vector that allowed for Tet-inducible transgene 
expression using a fusion of the Krüppel-associated box domain 
and the tetracycline repressor. We produced green fluorescent pro-
tein (GFP) expressing HD-Ad5/35 vectors and showed that back-
ground expression in 293 cells with Tet induction was suppressed.17 
However, when we replaced that GFP gene with the CCR5 ZFN gene, 
the resulting HD-Ad genomes isolated from purified particles dem-
onstrated genomic rearrangements and a deletion of parts of the 
ZFN cassette (Supplementary Figure S1).
Figure 1  miRNA expression profiling in 293-Cre versus CD34+ cells. (a) MicroRNA log2 intensity scatterplots of CD34+ cells (Y-axis) and 293-Cre cells 
(X-axis). miRNAs that fulfill our selection criteria (high expression level in 293-Cre cells and absent/low expression in CD34+ cells are labeled in red. 
293-Cre and CD34+ cells (pooled from four different donors) were infected with Ad vectors as described in the text. Twenty-four hours after infection, 
total RNA was isolated and hybridized to an array chip containing >2,000 miRNA probes. (b) Confirmation of array results by real-time PCR analysis for 
selected miRNA using the same RNA samples used for the array study. The Ct value was presented as average and SD from quadruplicate experiments. 
hsa-miR-130a-3p was selected as a positive control because, based on miRNA array and qRT-PCR assays, it was expressed at high levels in all 293 and 
CD34+ cell samples. The Ct value correlates inversely with the RNA concentration. n.d., not detectable.
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To generate HD-Ad5/35 vectors that express ENs in CD34+ cells, 
we developed a microRNA (miRNA)-regulated system to suppress 
expression of the payload in 293-cells while allowing it in CD34+ 
cells. This enabled us to produce HD-Ad5/35 vectors expressing 
either a functionally active ZFN or a TALEN at high titers without 
vector genome rearrangements during production. We demon-
strated that an HD-Ad5/35 vector expressing a CCR5 ZFN conferred 
the expected efficient knock out in primitive human HSCs without 
affecting the viability and differentiation potential of these cells.
ReSUlTS
To generate HD-Ad5/35 vectors that express ZFN or TALEN trans-
genes in human hematopoietic CD34+ stem cells, we used a miRNA- 
regulated gene expression system. Approaches for miRNA-based 
regulation were pioneered by Brown et al.24 in 2006. If the mRNA of a 
transgene contains a target site for a miRNA that is expressed at high 
levels in a given cell type, the mRNA will be degraded and transgene 
expression suppressed in this cell type. The power of this approach 
has been documented in a number of recent studies.25,26 We set out to 
establish a miRNA-regulated expression system that would suppress 
transgene expression in HD-Ad producer cells, i.e., 293-Cre cells, while 
conferring it in our target cells, i.e., human CD34+ HSCs by establishing 
the miRNA expression profile in both cell types. Because Ad infection 
could interfere with the miRNA expression profile, we infected 293-Cre 
cells with Ad5/35 helper virus at a multiplicity of infection (MOI) of 20 
pfu/cell, an MOI used for the amplification of HD-Ad vectors.27 CD34+ 
cells from four different adult (G-CSF  (granulocyte-colony stimulating 
factor)-mobilized) donors were pooled and infected with an HD-Ad5/35 
vector expressing GFP at an MOI of 2,000 viral particle (vp)/cell, an MOI 
that confers efficient transduction of CD34+ cells.18 Total RNA was puri-
fied 24 hours after Ad infection and hybridized onto array miRNA chips 
containing >2,000 different human miRNAs probes (Figure 1a). In total, 
there were eight candidate miRNAs (Figure 1a, red letters) with high-
level expression in 293-Cre cells, but absent or low expression in CD34+ 
cells. The expression levels of candidate miRNAs were measured by 
real-time PCR (Figure 1b). Hsa-miR-7-5p and hsa-miR-18a-5p were 
removed from the candidate list, because they were also expressed in 
CD34+ cells at relatively high levels. miR-96-5p shared the same seed 
sequence at the 5′ end of the miRNA (i.e., the sequence which critically 
determines miRNA target specificity)28 with other miRNAs. Therefore, 
we did not include miR-96-5p into our selection. We then selected two 
miRNAs (hsa-miR-183-5p and hsa-miR-218-5p), which had the highest 
Figure 2 Analysis of miRNA regulated transgene expression. (a) Schematic of Ad5/35 vectors used to test miRNA regulated expression. Description 
is in the text. The 3′ end of the GFP gene is linked to the 3′ untranslated region (UTR) of the globin gene. miRNA target sites were inserted into the 
3′UTR. The GFP mRNA transcribed from the EF1a promoter therefore contains miRNA target sites. In contrast, mCherry expression is not regulated 
by the selected miRNAs. (b) Transgene expression in 293-Cre cells. Cells were infected at the indicated MOIs with the Ad5/35 vector that lacks miRNA 
target sites (no miR) and the vectors containing the miRNA target sites. Shown is the GFP fluorescence intensity divided by the mCherry fluorescence 
intensity measured by flow cytometry at 48 hours after infection. N = 3. P values were calculated using unpaired t-test with unequal variance (GraphPad 
Prism 5 software GraphPad Software, San Diego, CA). The P values for “no miR” versus “miR218-183” are 0.12; 0.0012; 0.02; and 0.0016 for MOIs 2, 5, 10, 
and 20 pfu/cell, respectively. Note that the two promoters (PGK and EF1a) are differently regulated and require different transcription factors. For the 
vector without miR target sites, with increasing MOIs, i.e., transgene copy numbers, GFP levels increase to a much greater degree than mCherry levels. 
We speculate that the concentration of transcription factors that bind to the EF1a promoter is a limiting factor in 293 cells, particularly if the vector 
replicates. This is however not relevant for our study and conclusion, because we only compare different vectors at the same MOI. (c) Flow cytometry 
of transduced CD34+ cells 48 hours postinfection. Shown is the GFP/mCherry MFI ratio. N = 3. The transduction studies in 293 and CD34+ cells were 
performed with first-generation vectors. The titers are given in plaque-forming units (pfu). One pfu corresponds to 20 viral particles (vp). GFP, green 
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expression levels in 293-Cre cells and that were either undetectable 
(hsa-miR-183-5p) or expressed at the lowest detectable level (hsa-miR-
218-5p) in CD34+ cells. To establish the miRNA-regulation system, we 
inserted four target sites with 100% homology to the selected two 
miRNAs alone and in combination into the 3′ untranslated region (UTR) 
of the globin gene. The UTR was linked to the 3′ end of a GFP gene, 
which was under the control of an EF1α promoter, a promoter that is 
highly active in CD34+ cells (Figure 2a). The GFP expression cassettes 
were inserted into a first-generation Ad5/35 vector. The vectors also 
contained a PGK promoter-driven mCherry expression cassette that 
was not regulated by the selected miRNAs. Normalization of miRNA-
regulated GFP expression to mCherry expression allows adjusting for 
differences in transduction efficiency between different vectors and 
cell types. We transduced CD34+ cells and 293-Cre cells with the vec-
tors and analyzed GFP and mCherry expression 48 hours later by flow 
cytometry (Figure 2b,c). In 293-Cre cells, mCherry expression levels 
were comparable for all four vectors, while GFP expression was sup-
pressed by vectors that contained the miRNA target sites. Based on 
the mean fluorescence intensity ratio of GFP to mCherry, the greatest 
suppression was achieved with the vector that contained both the 
target sequence of miR183 and miR218 (Figure 2b). The difference in 
normalized GFP levels between the vector that contained the miR218 
target sites only and the vector that contained the combination of both 
miR218 and miR183 target sites is significant, and the P values decrease 
with increasing MOIs (MOI5: P = 0.047; MOI10: P = 0.033; and MOI20: 
P = 0.006), suggesting that miR183 target sites contribute to suppres-
sion of GFP expression.
Considering that first-generation Ad vectors replicate in 293-Cre 
cells and thus strongly express transgene products, the capabil-
ity of the miR-183/218-based system to control GFP expression 
in 293-Cre cells is notable. This is further corroborated by the 
observation that normalized GFP levels do not increase in an MOI-
dependent manner in 293-Cre cells. In contrast, in CD34+ cells 
both GFP and mCherry expression were comparably high for all 
vectors (Figure 2c).
Using the miRNA-183/218 regulated gene expression system, we 
generated an HD-Ad5/35 vector expressing a ZFN under the control 
of the EF1α promoter (Figure 3a). The ZFN was directed against the 
gene of the HIV coreceptor CCR5.11 The two ZFN subunits are linked 
through a self-cleaving picornavirus 2A peptide and are expressed 
as a poly-protein that is then cleaved. The miRNA-controlled ZFN 
expression cassette was inserted into a plasmid that, except the 
viral inverted terminal repeats (ITRs) and packaging signal, lacked 
any sequences encoding for viral proteins.29 The corresponding 
HD-Ad5/35.ZFNmiR vector (HD-ZFN) was produced in 293-Cre cells 
at high titers (1.88 × 1012 vp/ml). Restriction analysis of viral DNA iso-
lated from CsCl-gradient purified HD-ZFN particles did not reveal 
genomic rearrangements (Supplementary Figure S2a). To function-
ally test the HD-ZFN vector, we first performed transduction studies 
in MO7e cells, a CD34+ growth factor-dependent erythroleukemia 
cell line that is often used as a model for HSC gene therapy studies.30 
At day 2 posttransduction, half of the cells were used to analyze 
ZFN expression by western blot using antibodies against the FokI 
domain (Figure 3b). Genomic DNA was isolated from the other half 
Figure 3 Transduction studies with HD-Ad5/35.ZFNmiR. (a) Vector genome structure. The two ZFN subunits are linked trough a self-cleaving viral 2A 
peptide. The ZFN coding sequence is upstream of miR-183/218 target sites and 3′UTR. Both ZFN subunits are transcribed from the EF1a promoter. In 
CD34+ cells, the mRNA will not be degraded, and a polyprotein will be expressed which will subsequently be cleaved into the two ZFN subunits at the 
2A peptide. (b,d) Expression of ZFN protein in (b) MO7e cells or (d) CD34+ cells after transduction with the HD-Ad5/35.ZFNmiR vector (HD-ZFN) at the 
indicated MOIs. Cells were harvested 48 hours later, and cell lysates were analyzed by western blot with antibodies against the Fok1 domain. Actin B is 
used as loading control. (c,e) T7E1 nuclease assay. Genomic DNA from transduced (c) MO7e cells or (e) CD34+ cells was subjected to a PCR assay based 
on a T7E1 nuclease that detects mutations.11 PCR products were separated by polyacrylamide gel electrophoresis. Bands that correspond to disrupted 
ccr5 alleles are marked by arrows. The expected size of cleavage products is 141 and 124 bp. The numbers below the lanes indicate the % of disrupted 
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of cells and analyzed for ZFN cleavage by T7E1 nuclease assay spe-
cific for the CCR5-ZFN target site (Figure 3c). This analysis showed 
that HD-ZFN conferred site-specific DNA cleavage in >40% of ccr5 
alleles in MO7e cells. An analogous study was then performed with 
human CD34+ cells from two different donors (donor A and donor 
B). Studies with cells from donor A are shown in Figure 3d,e. In west-
ern blot analysis of cells collected 48 hours after infection, detect-
able FokI signals appeared when cells were infected at MOIs of 
≥5 × 103 vp/cell (Figure 3d). Analysis of genomic DNA for ccr5 modi-
fication showed a disruption frequency of 13, 8.9, and 8.1% for MOIs 
of 103, 5 × 103, and 104 vp/cell, respectively. Notably, the ccr5 disrup-
tion frequency did not increase with the MOI; it rather decreased 
most likely due to vector- or ZFN-related toxicity. Furthermore, gene 
disruption was seen in cells infected at an MOI of 103 vp/cell, i.e., an 
MOI at which ZFN expression was below the western blot detec-
tion level. The second study was performed with CD34+ cells from 
donor B. CD34+ cells from this donor were an aliquot from a CD34+ 
cell batch that was used for allogeneic HSC transplantation in can-
cer patients. The transduction efficacy with Ad5/35 and HD-Ad5/35 
vectors was comparable to that of CD34+ cells from donor A. These 
cells can therefore be used to assess potential cytotoxicity of vec-
tor transduction. However, the genome of donor B cells contained 
a small nucleotide polymorphism within the ccr5 gene close to the 
ZFN cleavage site (Supplementary Figure S3a). The T7E1 nuclease 
assay is not able to distinguish between the SNP and ZFN-mediated 
rearrangements and therefore shows ccr5 disruption in all samples, 
including untransduced cells (Supplementary Figure S3b).
To assess whether ZFN expression from HD-Ad5/35 vectors causes 
cytotoxicity in CD34+ cells at the doses we used, we performed flow 
cytometry for the apoptosis marker Annexin V at day 4 after trans-
duction. CD34+ cells used for this study were from donors A and B 
(Figure 4a,b). Although the outcome of the studies slightly differed 
between the two donors, HD-ZFN transduction did not significantly 
affect cell viability when compared to untransduced cells and con-
trol (HD-bGlob) vector transduced cells. In contrast, transduction 
of CD34+ with a first-generation Ad5/35 vector expressing the 
CCR5-ZFN11 increased the percentage of Annexin V-positive cells in 
a dose-dependent manner in this experimental set up (Figure 4c).
The next tasks were to show that HD-ZFN mediates CCR5 disrup-
tion in primitive HSCs and that transduction and ZFN expression do 
not affect the ability of these cells to proliferate and differentiate. 
To assess the latter, we subjected HD-ZFN-transduced CD34+ cells 
to a long-term culture initiating cell (LTC-IC) assay. This assay mea-
sures primitive HSCs based on their capacity to produce myeloid 
progeny for at least 5 weeks. Committed progenitors initially pres-
ent in the transduced CD34+ cell population will rapidly mature and 
disappear during the initial 3 weeks of culture due to their limited 
proliferative potential. The more primitive cells will be maintained 
throughout the duration of culture and generate a new cohort of 
committed progenitors (e.g., colony-forming cells), which can be 
later detected and enumerated at the end of the assay using pro-
genitor colony assays in semi-solid media. For both the control 
HD-bGlob and HD-ZFN vectors, transduction of CD34+ cells from 
donor A decreased the number of colonies compared to untrans-
duced controls whereby the differences were significant only for 
MOI 5,000 vp/cell (Figure 5a). Transduction of CD34+ cells from 
donor B with the control vector did not significantly affect colony 
formation, while transduction with HD-ZFN at an MOI of 1,000 vp/
cell significantly decreased it (Figure 5b). Transduction with FG-ZFN 
vector inhibited colony formation (Figure 5c).
To evaluate CCR5 disruption levels in LTC-IC, cells from all colonies 
in a plate were combined, genomic DNA was isolated, and subjected 
to T7E1 nuclease assay. The frequency of HD-ZFN-mediated ccr5 gene 
disruption in CFUs at the end of the assay was 23.7% (Figure 5d). This 
suggested that the vector targeted primitive CD34+ cells and that 
the gene modification is persistent in HSC progeny. To further sup-
port this, we studied whether the HD-ZFN vector is able to mediate 
CCR5 disruption in NOD/SCID repopulating cells (Figure  6a). This 
functional HSC assay is thought to potentially be predictive of the 
ability to repopulate conditioned recipients in human trials.31 For 
this assay, we transduced CD34+ cells from donor A with the control 
HD-bGlob vector or HD-ZFN vector at an MOI of 5,000 vp/cell for 24 
hours under low-cytokine conditions to prevent CD34+ cell differ-
entiation. Transduced cells were transplanted into sublethally irradi-
ated NOD/Shi0scid/IL-2Rγnull (NOG) mice. Engraftment of human 
cells was analyzed 6 weeks after transplantation by flow cytometry 
for human CD45+ cells in bone marrow, spleen, and peripheral blood 
mononuclear cells (PBMCs). (Notably, bone marrow engraftment 
rates with CD34+ cells from adult donors are usually lower than 
those achieved with umbilical cord-blood derived CD34+ cells). We 
found that ~6% of bone marrow cells were human CD45+ positive 
in mice that were transplanted with nontransduced CD34+ cells 
(Figure 6b). The average bone marrow engraftment rate of HD-ZFN 
transduced cells was 2.12%, which is about threefold lower than that 
Figure 4 Analysis of CD34+ cytotoxicity associated with HD-ZFN transduction. Studies were performed with CD34+ cells from donor A (a) and donor 
B (b). Shown is the percentage of Annexin V-positive cells at day 4 after transduction with an HD-Ad5/35 control vector containing the β-globin LCR 
(HD-bGlob) or the HD-ZFN vector at the indicated MOIs. Annexin V and 7AAD expression was analyzed by flow cytometry N = 3. (c) Cytotoxicity after 
infection of CD34+ cells with first-generation (FG-ZFN) and helper-dependent (HD-ZFN) Ad5/35 vectors expressing the CCR5 ZFN. CD34+ cells from 
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of untransduced cells. Interestingly, transduction with the HD-b Glob 
vector increased the engraftment rate. Analysis of human CD45+ cells 
in the spleen and PBMC showed similar engraftment rates, although 
the effect of HD-bGlob transduction was less pronounced in these 
tissues. For further analyses, human CD45+ cells were purified using 
magnetic-activated cell sorting. Human CD45+ cells were subjected 
to progenitor/colony assays to assess the presence of HSCs (Figure 
6c). Similar numbers of colonies were found in engrafted CD45+ cells 
from mice that received untransduced or HD-ZFN transduced CD34+ 
cells. Colony numbers were higher for the HD-bGlob group, suggest-
ing that this vector improves the survival of HSCs. The reason for this 
remains elusive at this point. To investigate the frequency of CCR5 
modification, human CD45+ cells were analyzed by T7E1 nuclease 
assay. We found the levels of ccr5 gene disruption to be 8.4 and 12% 
in two transplanted mice, respectively (Figure 6d). These data sug-
gest that although HD-ZFN transduction and/or ZFN expression may 
decrease the engraftment rate of CD34+ cells, ccr5 gene disruption 
was achieved in HSCs that persisted in transplanted mice for the time 
of analysis.
To show the versatility of our miRNA-based approach to regu-
late transgene expression, we produced a second vector express-
ing a TALEN targeting the DNase hypersensitivity region 2 (HS2) 
within the globin locus control region (LCR) (Figure 7a). The site was 
selected because it is thought that target DNA sequences are bet-
ter accessible to ENs when they are localized in active chromatin 
or DNase HS regions.32,33 We and others have shown in erythroid 
and HSC lines that the HS2 region is occupied by open chromatin 
marks.34–37 We have also previously shown that HD-Ad5/35 vectors 
carrying a 23-kb fragment of the β-globin LCR preferentially inte-
grated into the chromosomal β-globin LCR through chromatin teth-
ering to the HS2 area.18,34 The latter studies were done in MO7e cells. 
As with ZFN-expressing HD-Ad5/35 vectors, our earlier attempts to 
rescue HD-Ad5/35-TALEN virus vectors (without mRNA-mediated 
suppression in 293 cells) were unsuccessful.
To generate the HD-Ad5/35.TALENmiR (HD-TALEN) vector, the 3′ 
end of the TALEN mRNA was modified to contain miR-183/218 bind-
ing sites (Figure 7b). The HD-TALEN vector was produced at a high 
titer (2.5 × 1012 vp/ml) without detectable genome rearrangements 
(Figure 2b). After infection of MO7e cells with HD-TALEN at an MOI of 
1,000 vp/cell, TALEN expression was detected by western blot using 
an anti-hemagglutinin tag antibody (Figure 7c). T7E1 nuclease assay 
revealed ~50% modification of the HS2 target site in MO7e cells at 
day 2 after infection. The ability to place HS2-specific DNA breaks in 
combination with our globin LCR containing HD-Ad5/35 is relevant 
for targeted transgene insertion.
Taken together, our studies show the miRNA system is a robust 
platform for the production of HD-Ad5/35 vectors expressing ZFNs 
and TALENs.
DISCUSSION
Because ZFNs were the first ENs developed, a substantial amount 
of data regarding site-specific and off-target activity has been 
Figure 5 Analysis of LTC-IC. CD34+ cells were transduced with HD-bGlob and HD-ZFN at the indicated MOIs. Three days later, cells were transferred 
to LTC-IC medium and cultured for 5 weeks. A total of 3,000 LTC-IC cells were then plated in methylcellulose supplemented with growth factors and 
cytokines. Two weeks later, colonies were counted. Cells from all colonies per plate were combined, genomic DNA was isolated, and subjected to T7E1 
nuclease assay. (a,b) Numbers of colonies per plate for donor A and B, respectively. There was no difference in the ratio of BFU-E and CFU-GM colonies 
in the different groups. N = 3 plates. n.s., nonsignificant (P > 0.05), **P < 0.05. (c) Number of CFU from donor B cells transduced with FG-ZFN and HD-ZFN. 
(d) T7E1 nuclease assay. CD34+ cells from donor A were used for transduction with HD-bGlob and HD-ZFN at an MOI of 5,000 vp/cell. Genomic DNA 
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Figure 6 ccr5 Gene knock out in NOD/SCID repopulating cells. (a) Study design. Cryoconserved CD34+ cells from donor A were cultured overnight under low 
cytokine concentration conditions and transduced with HD-bGlob or HD-ZFN at an MOI of 5,000 vp/cell for 24 hours. Cells were then washed and transplanted 
into sublethally irradiated NOG mice. Six weeks later, animals were euthanized, and bone marrow cells, splenocytes, and PBMC were collected. The percentage 
of human cells in collected cells was measured by flow cytometry for the pan-leukocyte marker CD45. Human donor cells were purified by magnetic-activated 
cell sorting (MACS) using beads conjugated with anti-human CD45 antibodies. CD45+ cells were used for the T7E1 nuclease assay. (b) Engraftment rate based 
on the percentage of human CD45+ cells in total cells from bone marrow, spleen, and PBMCs. N = 3. (c) Number of colonies from MACS isolated human CD45+ 
from bone marrow cells in the bone marrow of transplanted mice. N = 3. The difference between “no Ad” and “HD-ZFN” is not significant (P = 0.061) (d) Analysis 
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Figure 7 Structure and functional analysis of an HD-Ad5/35 vector expressing a globin LCR-specific TALEN. (a) Target site of TALEN. Shown is the 
structure of the globin LCR with DNase hypersensitivity sites HS1 to HS5. The lower panel shows the 5′ sequence of the HS2 target site labeled by a 
horizontal arrow. The lines above and below the sequence indicate the binding sites of the two TALEN subunits, respectively. The vertical bold arrow 
marks the TALEN cleavage site. (b) Structure of the HD-Ad5/35.TALENmiR (HD-TALEN) genome. In analogy to the ZFN vector, the two TALEN subunits 
were linked through a 2A peptide at the 3′ end to the miR183/218 target sequence-containing 3′UTR. The N-terminus of TALEN (1) contained an 
influenza hemagglutinine (HA) tag. (c) Expression of TALEN in MO7e cells. Cells were infected at an MOI of 1,000 vp/cell, and cell lysates were analyzed 
by western blot with antibodies specific for HA-tag. (d) T7E1 nuclease assay analysis. Genomic DNA was isolated from MO7e cells 48 hours after infection 
at an MOI of 103, 2 × 103 vp/cell and subjected to PCR using globin LCR H2-specific primers. The expected length of PCR products is 608, 434, and 174 bp. 
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accumulated for these types of ENs. A ZFN targeting the HIV CCR5 
coreceptor gene was the first to be tested in clinical trials.12 This trial 
involved the ex vivo transduction of patient CD4+ T-cells with a CCR5-
ZFN expressing Ad5/35 vector. More recent efforts have focused on 
ccr5 gene knock out in HSCs. Targeting HSCs versus CD4+ T cells has 
a number of advantages: (i) As HSCs are a source for all blood cell 
lineages, CCR5 knock out would protect not only CD4 cells but also 
all remaining lymphoid and myeloid cell types that are potential tar-
gets for HIV infection. (ii) In contrast to CD4+ cell transplants, a single 
HSC transplant would potentially provide a lifelong source of HIV-
resistant cells to allow long-term protection or control of HIV/AIDS. 
The first successful attempt to achieve ZFN-mediated disruption of 
ccr5 gene sequences in HSCs was reported by Holt et al.3 in 2010. This 
study demonstrated engraftment of the modified HSCs in NOD/SCID/
IL2rγnull (NSG) mice resulting in resistance to CCR5-tropic HIV-1 infec-
tion. While encouraging, the data also indicated a number of poten-
tial problems, including the poor viability of cells transfected with 
the ZFN-expressing plasmid by electroporation in this experimental 
system. To address this problem, Li et al. used the Ad5/35 vector that 
was employed for CCR5 knock out in human T-cells. While efficient in 
T-cells, the Ad5/35 vector achieve less than 5% ccr5 gene disruption in 
HSCs.7 Reasons for this poor efficacy could include suboptimal expres-
sion of the ZFN from the promoter used, which was a minimal CMV 
promoter linked to tet-operator sequences. This promoter, in combi-
nation with doxycline induction, was employed by the minCMV-tetO 
promoter in combination with tet-repressor expressing 293 cells and 
was used to suppress ZFN expression in adenovirus producer cells. 
Previously, we showed that this promoter is active in only a very small 
subset of CD34+ cells after Ad5/35 infection in our experimental sys-
tem.17 Poor viability in the study by Li et al. could also be due to cyto-
toxicity associated with first-generation Ad5/35 vectors in HSCs. We 
attempted to address both of these problems. Instead of the minCMV-
TetO promoter we used the EF1a promoter, a promoter that is active 
in CD34+ and often used in HSC gene therapy studies.38 We also 
wanted to replace the first-generation Ad5/35 vector platform with 
helper-dependent HD-Ad5/35 vectors to avoid potential cytotoxic-
ity associated with leaky viral gene expression from first-generation 
vectors. Initial attempts to rescue first-generation or helper-depen-
dent Ad5/35 vectors expressing CCR5 ZFN under the EF1a promoter 
failed or resulted in rearranged genomes with deleted ZFN genes in 
the vectors. This supports the idea that of Ad genomes comprising a 
pair of ZFN sequences may be unstable, a notion which is further sup-
ported by the existence of two identical copies of FokI gene as well as 
eight ZFN DNA binding motifs in the vector genome, which can serve 
as substrates for intramolecular recombination. Recombination in Ad 
genomes is an often occurring event and a major means of Ad evolu-
tion. It is mediated by the unique mechanism of Ad DNA replication, 
which takes place in two steps.39 In the first stage, DNA synthesis is 
initiated by viral “terminal protein” and polymerase from both ITRs of 
the linear genome, resulting in a daughter strand that is synthesized 
in the 5′ to 3′ direction, displacing the parental strand with the same 
polarity. The displaced parental strand is a single-stranded molecule 
that self-anneals through the ITRs, which in turn serves as a primer for 
the second strand synthesis. We previously demonstrated that intra-
molecular annealing and recombination between repeat sequences 
inserted into the Ad genome occurs during the single-stranded stage 
of the Ad genome.40
To guard against the potential cytotoxicity of high level ZFN 
expression in 293-Cre cells in our system, we established a miRNA-
based gene regulation system to suppress the ZFN transgene. The 
system is based on profiling of miRNA expression in 293-Cre cells 
and human CD34+ cells pooled from different donors. Studies with 
reporter genes showed efficient suppression of a transgene that was 
regulated by hsa-miR-183-5p and hsa-miR-218-5p. While there was 
background expression of the miRNA-regulated GFP reporter gene, 
it did not increase in a dose-dependent manner or upon viral replica-
tion. The latter could be due to the high levels of miR-183 and -218 
in 293-Cre cells and complete saturation of the corresponding target 
sites. Importantly, the miR183/218-regulation system was sucessful 
for the generation of HD-Ad5/35 vectors expressing the CCR5 ZFN or 
the globin LCR TALEN. Potentially, our miRNA-regulated approach is 
also relevant for the production of lentivirus or rAAV vectors which 
also use 293 cells as production cells.
In transduction studies, we focused on HD-Ad5/35.ZFNmiR 
(HD-ZFN). ZFN expression analyzed at day 2 after infection was 
lower in CD34+ cells than in MO7e cells. This is in agreement with 
our previous studies with HD-Ad5/35.GFP vectors in which we 
showed that transduction of CD34+ cells results in GFP expres-
sion in ~60% of CD34+ cells and mean GFP fluorescence intensity 
levels that were about ~10-fold lower than that in MO7e cells. As 
a limiting factor, we have identified inefficient virus trafficking to 
nucleus.41 Li et al.7 showed that this can be, in part, overcome by 
incubation of CD34+ cells with protein kinase C (PKC) activators 
which has however the drawback that these compounds might 
affect HSC biology.
Analysis of ccr5 gene disruption at day 2 after HD-ZFN transduc-
tion did not show a correlation with ZFN expression level at this 
time point. Analysis at a later time point follow transduction poten-
tially would show a higher level of disruption. It is possible that cel-
lular factors, specifically proteins involved in nonhomologous end 
joining DNA repair limit the disruption efficiency rearrangement 
efficacy. Alternatively, considering that CD34+ cells is a highly het-
erogeneous cell population, it is possible that HD-Ad5/35 transduc-
tion, ZFN cleavage, and/or nonhomologous end joining occurs only 
in fraction of CD34+ cells. Importantly, our subsequent LTC-IC and 
NOG mice repopulation studies suggested that the targeted CD34+ 
cells contain primitive stem cells.
We found that HD-ZFN transduction decreased the engraftment 
rate, survival, and/or expansion of CD34+ cells in NOG mice in our 
system. This was not necessarily due to HD-Ad5/35 transduction 
and vector-associated toxicity per se, because engraftment rates 
were actually higher with HD-bGlob transduced CD34+ cells than 
with nontransduced cells. We therefore speculate that this is related 
to ZFN expression over an extended time period. Nonintegrating 
HD-Ad vector genomes are lost after several rounds of cell division, 
however, persist longer in nondividing cells such as hepatocytes.42 
Because HSCs are low proliferative, HD-Ad5/35 genomes could be 
maintained for longer time periods and thus express ZFN. For gene 
engineering purposes, it is sufficient that ZFNs are expressed only 
for a short time period. Future effort should focus on regulating the 
duration of ZFN expression from HD-Ad5/35 vectors.
It is noteworthy that we used in our studies CD34+ cells from adult 
G-CSF mobilized donors, a source that is easier available than fetal 
liver or cord blood derived CD34+ cells, which were used in previous 
studies with CCR5 ZFNs.2,3 A ccr5 gene disruption frequency of 12% 
in engrafted HSCs found in the bone marrow of transplanted NOG 
mice is clinically relevant for HIV therapy considering that these cells 
can give rise to multiple lineages, including lineages that represent 
targets and reservoirs for HIV.
Another avenue that we are following is to use the globin LCR-
specific TALEN to increase the site-specific integration of a donor 
HD-Ad5/35 vector through homologous recombination.18
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The HD-Ad5/35 vector platform for EN gene delivery to HSCs has 
major advantages over other delivery systems. (i) Most importantly, 
it allows for efficient targeting of primitive HSCs with less cytotoxic-
ity. (ii) The insert capacity of HD-Ad vectors is 30 kb, which allows the 
accommodation of several ENs and homologous donor templates. 
This is important for the simultaneous editing of multiple genes in 
HSCs for gene therapy purposes or to establish relevant models for 
multigenic human diseases. The use of HD-AD5/35 vector would also 
make it possible to combine both the EN expression cassette and the 
donor DNA sequences with extended homology regions into one vec-
tor. In this context is notable that the efficacy of homologous recom-
bination directly correlates with the length of the homology regions.16 
(iii) HD-Ad vectors allow for the transduction of target cells in vivo. 
HD-Ad5 vectors efficiently transduce hepatocytes in mice and nonhu-
man primates after intravenous injection.43,44 Our preliminary studies 
in human CD34+/NOG and human CD46-transgenic mice show that 
affinity-enhanced Ad5/35 and HD-Ad5/35 vectors can transduce 
G-CSF/AMD3100 mobilized HSCs after intravenous injection.21 HSC 
gene editing approaches involving the in vitro culture/transduction, 
and retransplantation into myelo-conditioned patients are technically 
complex and expensive. The in vitro culture of HSC in the presence of 
multiple cytokines affects the viability, pluripotency, and engraftment 
potency of HSCs. Furthermore, the need for myeloablative regimens 
creates additional risks for patients. Finally, the procedure is expensive 
and can only be performed in specialized institutions. Therefore, vec-
tors system that allow for in vivo HSC genome editing are of relevance.
In summary, we have developed a miRNA-regulated HD-Ad5/35 
vector platform for the expression of designed endonucleases 
in primitive HSCs. This vector system is a new important tool for 
genome engineering of HSCs for therapeutic purposes.
MATeRIAlS AND MeTHODS
Cells
293 cells, 293-C7-CRE45 cells were cultured in Dulbecco’s modified Eagle’s 
medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal calf 
serum (FCS) (HyClone, Logan, UT) 2 mmol/l l-glutamine, and Pen-Strep. 
Mo7e cells30 were maintained in RPMI 1640 medium containing 10% FCS, 
2 mmol/l l-glutamine, Pen-Strep, and granulocyte-macrophage colony 
stimulating factor (G-CSF) (0.1 ng/ml) (Peprotech, Rocky Hill, NJ). Primary 
human CD34+-enriched cells from G-CSF mobilized normal donors were 
obtained from the Fred Hutchinson Cancer Research Center Cell Processing 
Core Facility. We used PBMC-derived CD34+ cells from two different donors, 
designated as “donor A” and “donor B.” CD34+ cells were recovered from fro-
zen stocks and incubated overnight in Iscove’s modified Dulbecco’s medium 
(IMDM) supplemented with 20% FCS, 0.1 mmol/l 2-mercaptoethanol, stem 
cell factor (50 ng/ml), DNase I (100 µg/ml), 2 mmol/l l-glutamine, Flt3 ligand 
(Flt3L, 50 ng/ml), interleukin (IL)-3 (10 U/ml), and thrombopoietin (10 ng/ml). 
Cytokines and growth factors were obtained from Peptotech.
miRNA array
Array studies were performed using Agilent’s human miRNA (8 × 60 K) V18.0 
(Agilent Technologies, Santa Clara, CA) containing 2006 different human miRNA 
probes. Extraction of miRNA and RNA from Qiagen (Valencia, CA) RNAprotect 
cell reagent stabilized cells was performed according to the Qiagen miRNeasy 
kit protocol. RNA samples were frozen at −80 °C. Each slide was hybridized with 
100 ng Cy3-labeled RNA using miRNA Complete Labeling and Hyb Kit (Agilent 
Technologies) in a hybridization oven at 55 °C, 20 rpm for 20 hours according 
to the manufacturer’s instructions. After hybridization, slides were washed 
with Gene Expression Wash Buffer Kit (Agilent). Slides were scanned by Agilent 
Microarray Scanner and Feature Extraction software 10.7 with default settings. 
Raw data were normalized by Quantile algorithm, Gene Spring Software 11.0, 
Santa Clara, CA.
qRT-PCR for selected miRNAs
RNA prep concentration was measured using ScanDrop (Analytik Jena, Jena, 
Germany). The reverse transcription was performed using TaqMan miRNA 
Reverse Transcription Kit with miRNA-specific primers all purchased from 
Applied Biosystems (Foster City, CA), using 5 ng template, 4 °C 6 minutes, 16 
°C 30 minutes, 42 °C 30 minutes, and 85 °C 5 minutes. The real-time PCR was 
performed in quadruplicate with TaqMan 2× Universal PCR Master Mix with 
no AmpErase UNG on a 7900HT machine (Applied Biosystems), using 0.27 ng 
template in 10 µl reaction volume, 95 °C for 10 minutes, 40 cycles of 95 °C for 
15 seconds, 60 °C for 60 seconds. The Ct value was calculated at threshold 
equals 0.3 and with manual baseline start cycle at 3 and end cycle at 13. 
miRNA homology in the 5′ seed sequences was analyzed using “R software” 
(Beijing, China) and “microRNA” bioconductor package (Seattle, WA).28
Adenovirus vectors
Ad5/35-RG containing miRNA target sites. The GFP-mCherry cassette from 
pRG0
46 was transferred into the adenovirus shuttle plasmid pDeltaE1/Sp1 
(Microbix, Ontario, Canada). The following miRNA target sites were synthe-
sized and inserted into the AvrII/SmaI site of the shuttle vectors:
miR-183 target site: 5′ CTAGGATTATGGCACTGGTAGAATTCAC TACTTAT 
GGCACTGGTAGAATTCACTAC TTATGGCACTGGTAGAA TTCACTACTTATGGCA 
CTGGTAGAATTCACTATCGCCCGGG
miR-218 target site: 5′ CCTAGGAATTTGTGCTTGATCTAACCA TGTTTCATTG 
TGCTTGATCTAACCA TGTTTCATTGTGCT TGATCTAACCATGTTTCATTGTGCTTG 
ATCTAACCATGTATCGCCCGGG
miR-183/218 target site: 5′ CCTAGGATTATGGCACTGGTAGAATTCACTACT 




First-generation Ad5/35 virus vectors were generated and tested as 
described elsewhere.6
HD-Ad5/35-ZFN containing the miR-182/218-regulated CCR5 ZFN under EF1a 
promoter control. The shuttle plasmid for recombination in HD backbone 
vector was generated using pBluescript (pBS) plasmid. Briefly, recombi-
nation arms were amplified from pHCA plasmid containing stuffer DNA29 
and cloned into pBS generating pBS-Z for ZFN-CCR5 construct and pBS-T 
for Talen-LCR construct. 3′UTR and pA sequence was synthesized by Gen-
Script (Piscataway, NJ) and cloned into both shuttle vectors via AgeI and 
XhoI generating pBS-Z-3′UTR-pA and pBS-T-3′UTR-pA. Ef1a promoter was 
extracted from PJ204-EF1a-pA containing a 1,335 bp fragment of the EF1a 
promoter with BamHI and NheI, then inserted into respective sites in both 
shuttle plasmids generating pBS-Z-Ef1a and pBS-T-EF1a. ZFN-CCR5 frag-
ment from pBS-CCR5 (ref. 11) was digested with EcoRI and XbaI and cloned 
into the shuttle vector generating pBS-Ef1a-ZFN-CCR5. Finally, synthesized 
miR-183/218 tandem repeats flanked by NotI were cloned into its respec-
tive site in pBS-Ef1a-ZFN-CCR5 generating pBS-Ef1a-ZFN-CCR5-miR. The 
shuttle vector plasmids were linearized with BstBI and recombined with 
pHCA backbone vector in Escherichia coli BJ5183 cells. Recombined pHCA-
Ef1a-ZFN-CCR5-miR and pHCA -EF1a-Talen-LCR-miR were then linearized 
with PmeI and rescued in 293-Cre cells with helper virus (HV-Ad5/35) to 
generate HD-Ad5/35-EF1a-ZFN-CCR5-miR virus (HD-Ad5/35.ZFNmiR) and 
HD-Ad5/35-EF1a-Talen-LCR-miR virus (HD-Ad5/35Talen.miR).
HD-Ad5/35-TALEN containing the miR-182/218-regulated HS2-LCR TALEN un-
der EF1a promoter control. The HS2-LCR-specific TALEN was designed by 
ToolGen (Seoul, South Korea) as described previously.47 The TALEN recog-
nition sequences are shown in Figure 7a. The DNA-binding domains are 
fused with FokI. The N-terminus of the DNA-binding domain is tagged with 
a  hemagglutinin-tag and contains a nuclear localization signal. The TALEN 
cassette was under the control of the EF1a promoter and contained miR 
sites upstream of 3′UTR. The two TALEN were cloned into pBS-T-EF1a and 
linked via 2A peptide. Similar to the ZFN-CCR5 construct, miR 183/218 
 tandem repeats were synthesized and cloned into NotI site of pBS-EF1a-
Talen-LCR generating pBS-EF1a-Talen-LCR-miR. For virus rescue, the final 
plasmid was linearized with PmeI.
HD-Ad5/35.bGlob (HD-bGlob). This vector has been described previously.18 
It contains ~26 kb of the globin LCR. The β-globin promoter controls the 
expression of a GFP gene.
HD-Ad5/35 vectors were produced in 293-Cre cells27 with the helper virus 
Ad5/35-helper41 as described in detail elsewhere.27 Helper virus contami-
nation levels were determined as described elsewhere and were found to 
be <0.05%. DNA analyses of HDAd genomic structure were confirmed as 
described elsewhere.27
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Flow cytometric analysis
For cytotoxicity analysis, Ad-transduced CD34+ cells were stained with the 
AnnexinV/7AAD apoptosis kit (eBiosciences, San Diego, CA). For engraft-
ment analysis, cells derived from PBMCs, bone marrow, and spleen were 
stained with anti-hCD45-PE (BD Biosciences, San Jose CA). The data were 
then analyzed with FlowJo software (Ashland, OR).
Magnetic-activated cell sorting
Anti-human CD45–conjugated microbeads were from Miltenyi Biotech 
(Auburn, CA). Cell purification was performed according to the manufac-
turer’s protocol.
LTC-IC assay
Transduced CD34+ cells were incubated in cytokine containing IMDM for 48 
hours after which they were transferred to long-term culture initiating con-
ditions. Briefly, adherent murine bone M2-10B4 Fibroblast feeder cell layers 
were established as described by StemCell Technologies (Vancouver, BC). 
Transduced CD34+ cells were added to the feeder layer and incubated for 5 
weeks in human long-term culture initiating medium with 10−6 mol/l hydro-
cortisone (StemCell Technologies), with weekly half medium changes. After 5 
weeks, cells were collected and subjected to colony-forming unit assay.
Colony-forming unit assays
For colony forming unit assay, 2 × 104 cells were transferred from LTC-IC 
into MethoCult GF H4434 medium (StemCell Technologies) in a humidified 
atmosphere of 5% CO2 at 37 °C in the presence of the following cytokines: 
IL-3, 50 U/ml; SCF, 50 ng/ml; Epo, 2 U/ml; and G-CSF, 6.36 ng.
Western blot
Cell pellets in ice-cold phosphate-buffered saline containing protease inhib-
itors (Complete Protease Inhibitor Cocktail, Roche, Mannheim, Germany) 
were sonicated, and the protein containing supernatant stored at −80 °C. A 
total of 20 μg of total protein was used for the western blot analysis. Proteins 
were separated by polyacrylamide gel electrophoresis using 4–15% gradi-
ent gels (BioRad, Hercules, CA), followed by transfer onto nitrocellulose 
membranes according to the supplier’s protocol (Mini ProteanIII; BioRad). 
Membranes were blocked in 5% nonfat dry milk (Bio-Rad) and washed in 
Tris-saline with 0.1% Tween-20. Membranes were incubated with anti-FokI 
antibody (Sangamo BioSciences, Richmond, CA), anti-hemagglutinin tag 
(Roche), or anti-β-actin (Sigma Aldrich, St Louis, MO). Membranes were 
developed with ECL plus reagent (Amersham, Buckinghamshire, UK).
Mismatch sensitive nuclease assay T7E1 assay
Genomic DNA was isolated as previously described.48 CCR5 or LCR region was 
amplified. Primers for detection of CCR5 disruption were described previ-
ously.49 Primers for HS-LCR site analysis were: 5′aaatcttgaccattctccactctc and 
5′GGAGACACACAGAAATGTAACAGG. PCR products were hybridized and 
treated with 2.5 units of T7E1 endonuclease (NEB, Ipswich, MA). Digested PCR 
products were resolved by 10% Tris-borate EDTA buffer (TBE) polyacrylamide 
gel electrophoresis (Biorad) and stained with ethidium bromide. Band inten-
sity was analyzed using ImageQuant software (Pittsburgh, PA).
Animal studies
All experiments involving animals were conducted in accordance with the 
institutional guidelines set forth by the University of Washington. Mice were 
housed in specific pathogen-free facilities. The immunodeficient NOG mice 
(strain name: NOD/Shi-scid/IL-2Rγnull) were obtained from the Jackson 
Laboratory (Bar Harbor, ME).
CD34+ cell transplantation
Cryo-conserved CD34+ cells were thawed in phosphate-buffered saline sup-
plemented with 1% heat-inactivated FCS. Freshly thawed cells were cultured 
overnight in IMDM containing 10% heat-inactivated FCS, 10% bovine serum 
albumin, 4 mmol/l glutamine and penicillin/streptomycin, as well as human 
cytokines (TPO, 5 ng/ml; SCF, 25 ng/ml; IL-3, 20 ng/ml; and Flt3L, 50 ng/ml). 
The next day, cells were infected with HD-bGlob or HD-ZFN at an MOI of 5,000 
vp/cell and incubated for 24 hours. Uninfected cells were used as control. The 
next day, NOG recipient mice received 300 Rad/3 Gy total body irradiation. 
Twenty-four hours postinfection, 3 × 105 transduced CD34+ cells were mixed 
with 2.5 × 105 freshly collected bone marrow cells of nonirradiated NOG mice 
and injected intravenously into recipient mice at 4 hours postirradiation. Six 
weeks after bone marrow transplantation, the engraftment rate was assayed 
as follows: blood samples were drawn, red blood cells were lysed, and the 
remaining cells were stained with PE-conjugated anti human CD45 antibod-
ies and analyzed via flow cytometry. Six weeks after transplantation, bone 
marrow cells were subjected to double sorting with anti hCD45 (Miltenyi) 
beads and seeded on methylcellulose. After 2 weeks, colonies were counted 
and subjected to T7E1 nuclease assay.
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